Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Cancer Research

Abstract P75: THE ROLE OF SETD2 IN THE MOLECULAR ONCOGENESIS OF GLIOMA THROUGH m6A RNA MODIFICATION

View Full Paper
Ask AI
Bookmark
Share

Authors

SKSubhadra KumariMSM. Srinivasan

Discussion

Loading...

Member takes

Overview

Observational analysis highlights SETD2's impact on m6A RNA methylation in glioma, suggesting new therapeutic targets.

Key Points

  • SETD2 disruption reduces m6A methylation, leading to decreased glioma cell proliferation and invasion.
  • Knocking down SETD2 led to a significant reduction in the expression of key m6A writers METTL3 and METTL14.
  • This study illustrates SETD2's critical role in glioma oncogenesis through its regulation of RNA modifications.
  • The findings may inform future therapeutic strategies targeting m6A methylation in glioblastoma.

Cite This Study

Kumari et al. (2025) studied this question.

synapsesocial.com/papers/68c23ed7b210217d64794a3ahttps://doi.org/10.1158/1538-7445.fcs2024-p75
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1M6A RNA METHYLATION AS A THERAPEUTIC TARGET IN HIGH GRADE GLIOMA2025
  2. 2EXPLORING THE GLIOMA M6A RNA EPITRANSCRIPTOME WITH DIRECT RNA SEQUENCING2025
  3. 360 INVESTIGATING SETD2 MUTATIONS IN NEURODEVELOPMENT USING CEREBRAL ORGANOID MODELS2025
  4. 4METTL3-mediated m 6 A modification of DNMT1 enhances ovarian cancer progression2025
  5. 5SETD2 suppresses tumorigenesis in a KRASG12C-driven lung cancer model and its catalytic activity is regulated by histone acetylation2025